TLS as Predictors and Targets in Neoadjuvant Chemoimmunotherapy for NSCLC

Area of Science:

• Immunology
• Oncology
• Cancer Research

Background:

• Tertiary lymphoid structures (TLS) are crucial for antitumor immunity in non-small cell lung cancer (NSCLC).
• TLS presence and maturation correlate with better outcomes and response to immune checkpoint inhibitors.
• Challenges include dynamic monitoring, understanding regulatory mechanisms, and standardizing assessment.

Purpose of the Study:

• To highlight the prognostic and therapeutic potential of TLS in NSCLC neoadjuvant chemoimmunotherapy.
• To identify obstacles hindering clinical translation and propose solutions.
• To outline future research priorities for leveraging TLS in precision cancer immunotherapy.

Main Methods:

• Review of current evidence on TLS in NSCLC.
• Discussion of limitations in monitoring and mechanistic understanding.
• Integration of multimodal technologies (imaging, transcriptomics, digital pathology) and AI.

Main Results:

• TLS are organized lymphoid aggregates that enhance local immune responses.
• Current methods lack dynamic monitoring and standardized assessment.
• Multimodal technologies and AI offer potential for refined TLS characterization.

Conclusions:

• TLS are promising biomarkers and therapeutic targets in NSCLC.
• Standardized assessment and dynamic monitoring are crucial for clinical translation.
• Future research should focus on multi-center trials and combinatorial therapies targeting TLS.